Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.

Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D.

Br J Clin Pharmacol. 2010 Nov;70(5):656-63. doi: 10.1111/j.1365-2125.2010.03743.x.

2.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group..

Cancer. 2003 Jun 15;97(12):3090-8.

3.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
4.

Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting.

Zick SM, Ruffin MT, Lee J, Normolle DP, Siden R, Alrawi S, Brenner DE.

Support Care Cancer. 2009 May;17(5):563-72. doi: 10.1007/s00520-008-0528-8. Epub 2008 Nov 13.

5.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group..

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
6.

Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.

Cruz FM, de Iracema Gomes Cubero D, Taranto P, Lerner T, Lera AT, da Costa Miranda M, da Cunha Vieira M, de Souza Fêde AB, Schindler F, Carrasco MM, de Afonseca SO, Pinczowski H, del Giglio A.

Support Care Cancer. 2012 Mar;20(3):601-6. doi: 10.1007/s00520-011-1138-4. Epub 2011 Apr 5.

PMID:
21465325
7.
8.

Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).

Hesketh PJ, Morrow G, Komorowski AW, Ahmed R, Cox D.

Support Care Cancer. 2012 Oct;20(10):2633-7. doi: 10.1007/s00520-012-1527-3. Epub 2012 Jun 24.

PMID:
22733373
9.

Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients.

Levitt M.

Cancer Treat Rev. 1982 Dec;9 Suppl B:49-53. No abstract available.

PMID:
6299556
11.

Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.

Shih V, Wan HS, Chan A.

Ann Pharmacother. 2009 Mar;43(3):444-52. doi: 10.1345/aph.1L437. Epub 2009 Feb 3.

PMID:
19193584
13.

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.

Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK.

Support Care Cancer. 2012 Jan;20(1):107-17. doi: 10.1007/s00520-010-1073-9. Epub 2011 Jan 22.

15.

Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial.

Panahi Y, Saadat A, Sahebkar A, Hashemian F, Taghikhani M, Abolhasani E.

Integr Cancer Ther. 2012 Sep;11(3):204-11. doi: 10.1177/1534735411433201. Epub 2012 Feb 7.

PMID:
22313739
17.

A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting.

Jones SE, Durant JR, Greco FA, Robertone A.

Cancer Treat Rev. 1982 Dec;9 Suppl B:45-8. No abstract available.

PMID:
6299555
18.

The cost of chemotherapy-induced nausea and vomiting in Italy.

Ballatori E, Roila F, Ruggeri B, Porrozzi S, Iannopollo M, Soru G, Cruciani G, Daniele B, Locatelli MC, Pellissier J, Deuson R.

Support Care Cancer. 2007 Jan;15(1):31-8. Epub 2006 Jun 21.

PMID:
16788840
19.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

20.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ.

Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1.

PMID:
19568773

Supplemental Content

Support Center